266 related articles for article (PubMed ID: 12927430)
1. Proteomic patterns of tumour subsets in non-small-cell lung cancer.
Yanagisawa K; Shyr Y; Xu BJ; Massion PP; Larsen PH; White BC; Roberts JR; Edgerton M; Gonzalez A; Nadaf S; Moore JH; Caprioli RM; Carbone DP
Lancet; 2003 Aug; 362(9382):433-9. PubMed ID: 12927430
[TBL] [Abstract][Full Text] [Related]
2. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
3. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
Yanagisawa K; Tomida S; Shimada Y; Yatabe Y; Mitsudomi T; Takahashi T
J Natl Cancer Inst; 2007 Jun; 99(11):858-67. PubMed ID: 17551146
[TBL] [Abstract][Full Text] [Related]
4. Proteomic patterns of preinvasive bronchial lesions.
Rahman SM; Shyr Y; Yildiz PB; Gonzalez AL; Li H; Zhang X; Chaurand P; Yanagisawa K; Slovis BS; Miller RF; Ninan M; Miller YE; Franklin WA; Caprioli RM; Carbone DP; Massion PP
Am J Respir Crit Care Med; 2005 Dec; 172(12):1556-62. PubMed ID: 16179643
[TBL] [Abstract][Full Text] [Related]
5. MALDI-ToF mass spectrometry for the rapid diagnosis of cancerous lung nodules.
Brégeon F; Brioude G; De Dominicis F; Atieh T; D'Journo XB; Flaudrops C; Rolain JM; Raoult D; Thomas PA
PLoS One; 2014; 9(5):e97511. PubMed ID: 24830707
[TBL] [Abstract][Full Text] [Related]
6. Application of serum SELDI proteomic patterns in diagnosis of lung cancer.
Yang SY; Xiao XY; Zhang WG; Zhang LJ; Zhang W; Zhou B; Chen G; He DC
BMC Cancer; 2005 Jul; 5():83. PubMed ID: 16029516
[TBL] [Abstract][Full Text] [Related]
7. Proteomic screening of completely resected tumors in relation to survival in patients with stage I non-small cell lung cancer.
Oshita F; Morita A; Ito H; Kameda Y; Tsuchiya E; Asai S; Miyagi Y
Oncol Rep; 2010 Sep; 24(3):637-45. PubMed ID: 20664968
[TBL] [Abstract][Full Text] [Related]
8. Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease.
Liao CC; Ward N; Marsh S; Arulampalam T; Norton JD
BMC Cancer; 2010 Aug; 10():410. PubMed ID: 20691062
[TBL] [Abstract][Full Text] [Related]
9. Matrix-assisted laser desorption/ionization mass spectrometry reveals decreased calcylcin expression in small cell lung cancer.
Lee HS; Park JW; Chertov O; Colantonio S; Simpson JT; Fivash MJ; Yoo CW; Lee GK; Zo JI; Kim HT; Kim HK
Pathol Int; 2012 Jan; 62(1):28-35. PubMed ID: 22192801
[TBL] [Abstract][Full Text] [Related]
10. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry.
Zhukov TA; Johanson RA; Cantor AB; Clark RA; Tockman MS
Lung Cancer; 2003 Jun; 40(3):267-79. PubMed ID: 12781425
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of S100A7 associated with lung squamous cell carcinoma metastasis to brain.
Zhang H; Wang Y; Chen Y; Sun S; Li N; Lv D; Liu C; Huang L; He D; Xiao X
Lung Cancer; 2007 Jul; 57(1):37-45. PubMed ID: 17418446
[TBL] [Abstract][Full Text] [Related]
12. Chaperonin (HSP60) and annexin-2 are candidate biomarkers for non-small cell lung carcinoma.
Ağababaoğlu İ; Önen A; Demir AB; Aktaş S; Altun Z; Ersöz H; Şanl A; Özdemir N; Akkoçlu A
Medicine (Baltimore); 2017 Feb; 96(6):e5903. PubMed ID: 28178129
[TBL] [Abstract][Full Text] [Related]
13. Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer.
Yang L; Tang C; Xu B; Wang W; Li J; Li X; Qin H; Gao H; He K; Song S; Liu X
PLoS One; 2015; 10(6):e0128970. PubMed ID: 26047516
[TBL] [Abstract][Full Text] [Related]
14. Proteomic profiling of cancer biomarkers.
Shau H; Chandler GS; Whitelegge JP; Gornbein JA; Faull KF; Chang HR
Brief Funct Genomic Proteomic; 2003 Jul; 2(2):147-58. PubMed ID: 15239937
[TBL] [Abstract][Full Text] [Related]
15. [Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing non-small cell lung cancer patients from healthy people].
Yang SY; Xiao XY; Zhang WG; Sun XZ; Zhang LJ; Zhang W; Zhou B; Yang DC; He DC
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Jan; 29(1):31-4. PubMed ID: 16638298
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis of gliomas.
Whittle IR; Short DM; Deighton RF; Kerr LE; Smith C; McCulloch J
Br J Neurosurg; 2007 Dec; 21(6):576-82. PubMed ID: 18071984
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis of resectable non-small cell lung cancer: post-resection serum samples may be useful in identifying potential markers.
Rathinam S; Ward DG; James ND; Rajesh PB
Interact Cardiovasc Thorac Surg; 2011 Jul; 13(1):3-6. PubMed ID: 21525028
[TBL] [Abstract][Full Text] [Related]
18. Proteomic strategies for the characterization and the early detection of lung cancer.
Massion PP; Caprioli RM
J Thorac Oncol; 2006 Nov; 1(9):1027-39. PubMed ID: 17409991
[TBL] [Abstract][Full Text] [Related]
19. MALDI profiling of human lung cancer subtypes.
Gámez-Pozo A; Sánchez-Navarro I; Nistal M; Calvo E; Madero R; Díaz E; Camafeita E; de Castro J; López JA; González-Barón M; Espinosa E; Fresno Vara JA
PLoS One; 2009 Nov; 4(11):e7731. PubMed ID: 19890392
[TBL] [Abstract][Full Text] [Related]
20. Proteomic patterns analysis with multivariate calculations as a promising tool for prompt differentiation of early stage lung tissue with cancer and unchanged tissue material.
Waloszczyk P; Janus T; Alchimowicz J; Grodzki T; Borowiak K
Diagn Pathol; 2011 Mar; 6():22. PubMed ID: 21418626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
